Zimmer Biomet Holdings, Inc. (NYSE:
ZBH) is included on our list of the
best undervalued wide moat stocks.
On January 13, 2026, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) laid out cautious expectations for 2026 at the 44
th Annual J.P. Morgan Healthcare Conference, according to
The Fly. While we don’t have specific details at this time, the company said its guidance will reflect the scale of the internal changes it has planned for 2026.
This caution follows the November 2025 guidance revision, where management lowered the upper end of its 2025 organic revenue growth forecast to 4.00% from 4.50% due to weaker demand in Latin America and emerging European markets. However, overall revenue growth estimates were kept stable due to favorable currency impacts. Management highlighted last-minute cancellations of distributor orders from the Middle East and Eastern Europe as a key factor.
Previously, on January 9, 2026, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) saw Bernstein raise its price target from $97.00 to $99.00, while reiterating its ‘Market Perform’ rating. The company noted improving clarity in macro and policy uncertainties for U.S. healthcare stocks.
On December 23, 2025, JPMorgan maintained its ‘Neutral’ rating on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) with a $100 price target. The firm sees 2026 as a pivotal year presenting growth opportunities, while fundamentals remain in good shape.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) focuses on designing, manufacturing, and marketing orthopedic, spine, dental, and surgical products worldwide.
While we acknowledge the potential of ZBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 7 Best Rising Tech Stocks to Buy Now and
12 Best Multibagger Stocks to Buy Heading into 2026.
Disclosure: None.
